Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20. März 2024 10:20 ET
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18. März 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08. März 2024 16:15 ET
|
PharmAla Biotech
PharmAla provides corporate update following AGM
PharmAla named an Intellectual Property Ontario Client
22. Februar 2024 08:55 ET
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
20. Februar 2024 08:55 ET
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09. Februar 2024 08:10 ET
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31. Januar 2024 10:58 ET
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25. Januar 2024 12:09 ET
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
24. Januar 2024 09:35 ET
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
08. Januar 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"